Sellas Life Sciences receives IDMC recommendation to continue phase 3 REGAL trial in acute myeloid leukaemia

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

drugs.com - 24/Jun 23:06

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...

University of Nebraska Medical Center enrolls patient for RenovoRx's pivotal phase III TIGeR─PaC trial

pharmabiz.com - 28/Jun 00:00

RenovoRx, Inc, a clinical─stage biopharmaceutical company developing novel precision oncology therapies based on a local drug─delivery platform,...

Cartesian Therapeutics doses first patient in phase 2 clinical trial of Descartes─08 to treat systematic lupus erythematosus

pharmabiz.com - 00:00

Cartesian Therapeutics, Inc, a clinical─stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, announced that the first...

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

mangaloremirror.com - 02/Jul 12:51

MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...

First Patient Dosed in the MAD Part 2 Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

drugs.com - 26/Jun 19:06

CAMBRIDGE, Mass., June 26, 2024. NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on transforming cardiometabolic...

First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus

drugs.com - 03/Jul 04:07

GAITHERSBURG, Md., July 02, 2024. artesian Therapeutics, Inc. (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell...

Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

drugs.com - 02/Jul 04:07

DAEJEON, South Korea, July 2, 2024. PharmAbcine, Inc. ("PharmAbcine" or the "Company") (KOSDAQ: 208340), a clinical-stage public company developing...

Syneos Health - USA: Principal Clinical Trial Manager - Early Phase

pharmiweb.com - 28/Jun 00:00

Competitive: Syneos Health - USA: Principal Clinical Trial Manager - Ophthalmology Syneos Health® is a leading fully integrated biopharmaceutical...

Synaptogenix gets US FDA authorization of IND application for clinical trial for Bryostatin─1 to treat multiple sclerosis

pharmabiz.com - 01/Jul 00:00

Synaptogenix, Inc., an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, announced that the Food & Drug...

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

financialpost.com - 21/Jun 20:01

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU...

Rubriques :